Metabolism - Clinical and Experimental
Volume 44, Issue 12 , Pages 1548-1552 , December 1995

Beneficial effect of a moderately energy-restricted diet on fibrinolytic factors in non-obese men

  • Erica J.M. Velthuis-te Wierik

      Affiliations

    • Corresponding Author InformationAddress reprint requests to Erica J.M. Velthuis-te Wierik, MSc, TNO Nutrition and Food Research Institute, Department of Physiology and Kinetics, PO Box 360, 3700 AJ Zeist, The Netherlands.
    • Netherlands Organization for Applied Scientific Research (TNO) Nutrition and Food Research Institute, Zeist, The Netherlands
    • TNO Prevention and Health, Gaubius Institute, Leiden, The Netherlands
    • ,
  • Piet Meijer

      Affiliations

    • Netherlands Organization for Applied Scientific Research (TNO) Nutrition and Food Research Institute, Zeist, The Netherlands
    • TNO Prevention and Health, Gaubius Institute, Leiden, The Netherlands
    • ,
  • Cornelis Kluft

      Affiliations

    • Netherlands Organization for Applied Scientific Research (TNO) Nutrition and Food Research Institute, Zeist, The Netherlands
    • TNO Prevention and Health, Gaubius Institute, Leiden, The Netherlands
    • ,
  • Henk van den Berg

      Affiliations

    • Netherlands Organization for Applied Scientific Research (TNO) Nutrition and Food Research Institute, Zeist, The Netherlands
    • TNO Prevention and Health, Gaubius Institute, Leiden, The Netherlands

Received 15 November 1994 ,Accepted 30 March 1995.

References 

  1. Weindruch R, Walford RL. The Retardation of Aging and Disease by Dietary Restriction. Thomas: Springfield, IL; 1988;
  2. Abbate R, Prisco D, Rostagno C, et al.  Age-related changes in the hemostatic system. Int J Clin Lab Res. 1993;23:1–3
  3. Potter van Loon BJ, Kluft C, Radder JK, et al.  The cardiovascular risk factor plasminogen activator inhibitor type 1 is related to insulin resistance. Metabolism. 1993;42:945–949
  4. Velthuis-te Wierik EJM, van den Berg H, Schaafsma G, et al.  Energy restriction, a useful intervention to retard human aging?. In: Results of a feasibility study. ed 3. Eur J Clin Nutr. 48:1994;p. 138–148
  5. WHO Study Group . Diabetes mellitus. WHO Tech Rep Set. 1985;727:
  6. Verheijen JH, Chang GTG, Kluft C. Evidence for the occurrence of a fast-acting inhibitor for tissue-type plasminogen activator in human plasma. Thromb Haemost. 1984;51:392–395
  7. Meijer P, Pollet DE, Wauters J, et al.  Specificity of antigen assays of plasminogen activator inhibitor in plasma: Innotest PAI-1 immunoassay evaluated. Clin Chem. 1994;40:110–115
  8. Meijer P, Boon R, Jie AFH, et al.  Bioimmunoassay for tissue-type plasminogen activator (t-PA) in human plasma: Evaluation of blood sampling and handling procedures and comparison with other t-PA activity methods. Fibrinolysis. 1992;6(suppl 3):97–99
  9. Prisco D, Chiaranti E, Boddi M, et al.  Predictive value for thrombic disease of plasminogen activator inhibitor-1 plasma levels. Int J Clin Lab Res. 1993;23:78–82
  10. Ogston D, McAndrew GM. Fibrinolysis in obesity. Lancet. 1964;2:1205–1207
  11. Meade TW, Chakrabarti R, Haines AP, et al.  Characteristics affecting fibrinolytic activity and plasma fibrinogen concentrations. Br Med J. 1979;1:153–156
  12. Heinrich J, Nguyên T, Kokott R, et al.  Interrelationships between coronary risk factors and the fibrinolytic system. Fibrinolysis. 1990;4(suppl 1):37; abstr
  13. Vague P, Juhan-Vague I, Aillaud F, et al.  Correlation between blood fibrinolytic activity, plasminogen activator inhibitor level, plasma insulin level, and relative body weight in normal and obese subjects. Metabolism. 1986;35:250–253
  14. McGill JB, Schneider DJ, Arfken CL, et al.  Factors responsible for impaired fibrinolysis in obese subjects and NIDDM patients. Diabetes. 1994;43:104–109
  15. Palareti G, Legnani C, Poggi M, et al.  Prolonged very low calorie diet in obese subjects reduces factor VII and PAl but not fibrinogen levels. Fibrinolysis. 1994;8:16–21
  16. Folsom AR, Qamhieh HT, Wing RR, et al.  Impact of weight loss on plasminogen activator inhibitor (PAI-1), factor VII, and other hemostatic factors in moderately overweight adults. Arterioscler Thromb. 1993;13:162–169
  17. Primrose JN, Davies JA, Prentice CRM, et al.  Reduction in factor VII, fibrinogen and plasminogen activator inhibitor-1 activity after surgical treatment of morbid obesity. Thromb Haemost. 1992;68:396–399
  18. Alessi MC, Juhan-Vague I, Kooistra T, et al.  Insulin stimulates the synthesis of plasminogen activation inhibitor 1 by the human hepatocellular cell line Hep G22. Thromb Haemost. 1988;60:491–494
  19. Smith U. Carbohydrates, fat and insulin. Am J Clin Nutr. 1994;59:686S–689S (suppl)
  20. Kluft C. Constitutive synthesis of tissue-type plasminogen activator (t-PA) and plasminogen activator inhibitor type 1 (PAIl): Conditions and therapeutic targets. Fibrinolysis. 1994;2:1–17 (suppl)
  21. Kluft C, Potter van Loon BJ, de Maat MPM. Insulin resistance and changes in haemostatic variables. Fibrinolysis. 1992;6(suppl 3):1116

PII: 0026-0495(95)90073-X

Metabolism - Clinical and Experimental
Volume 44, Issue 12 , Pages 1548-1552 , December 1995

Article Tools